Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Marijuana Use and Health Behaviors in a US Clinic Sample of Patients With Sickle Cell Disease
source: PloS One
year: 2020
authors: J. Deanna Wilson, Lydia H. Pecker, Sophie Lanzkron, Shawn M. Bediako, Dingfen Han, Mary Catherine Beach
summary/abstract:Introduction:
As marijuana use becomes more common, it is essential clinicians understand the relationship between marijuana use and health behaviors.
Methods:
Using a retrospective cohort of adolescents and adults with sickle cell disease (SCD) stratified into a young (<25 years) and older cohort (> = 25 years), we conducted multiple linear regression examining relationship of marijuana use (independent variable) on each dependent variable (SCD self-management score and pain management).
Results:
Among young cohort, 16.9% used marijuana compared to 21.8% of older cohort. The younger cohort reporting marijuana use had lower mean self-care scores (β = -2.74;p = 0.009) and were more likely to have admissions to the hospital for pain (β = 0.87;p = 0.047) compared to non-users. In contrast, the older cohort reporting marijuana use had more days treating pain at home (β = 0.44;p = 0.035).
Conclusions:
Only a minority of patients with SCD reported lifetime marijuana use. Among those reporting marijuana use, there were different associations with self-care and health-related behaviors by age. The older cohort who endorsed marijuana use reported more days of treating pain at home, although this did not translate into increased acute care visits for pain crisis. Among youth, endorsing marijuana use was associated with worse SCD self-care.
DOI: 10.1371/journal.pone.0235192
read more
Related Content
-
Outcomes of an Emergency Department Observation Unit–Based Pathway for the Treatment of Uncomplicated Vaso-Occlusi...Study objective: This was a prospective...
-
Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients With Sickle Cell Disease: A Retros...Background/Objectives: Among sickle cel...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.